CPML - Core C: Bioinformatics & Biostatistical Core

点击翻译按钮获取中文摘要

ABSTRACT – CORE C The three research projects outlined in this P50 Center proposal use multi-dimensional genomic and epigenomic assays, based on next-generation sequencing and microarray approaches (implemented in Core B), to gain understanding of the inherited variations and somatically acquired genetic and epigenetic alterations that drive treatment response of pediatric and adult acute lymphoblastic leukemia (ALL). The Bioinformatics/Biostatistics Core (Core C) provides biostatistical and bioinformatic support to ensure each project generates high quality data with analytical accuracy and reproducibility. Core C includes designated scientists to analyze genomic and epigenetic data for each project; to provide uniform and high quality approaches to variant calling, annotation, and functional assessments for germline and somatic tumor variations; and to perform statistical analyses. Working closely with Cores A and B, they develop and provide critical infrastructure necessary for data management and facilitate cross-project and public data sharing. Together with the project Leaders and Investigators, using statistically sound analyses, Core C will identify important biological processes involved in the classification and treatment response of ALL and determine the genetic and epigenetic markers that are associated with discrete phenotypes defined in the Projects: in vivo response (Project 1), drug sensitivitity (Project 2), and adverse effects (Project 3). Core C will integrate cross- platform genomic, transcriptomic, and epigenomic data. Core C also provides critical input on study design and power estimates for both clinical and preclinical aims of the Projects. In Aim 3, Core C will coordinate addressing the Center's overarching goal of using genome variations identified in the Projects to integrate clinical and genomic data for designing precision medicine approaches that can be used to improve treatment outcomes for children and adults with ALL.